BR0015025A - Solução oral contendo galantamina e um agente adoçante - Google Patents
Solução oral contendo galantamina e um agente adoçanteInfo
- Publication number
- BR0015025A BR0015025A BR0015025-8A BR0015025A BR0015025A BR 0015025 A BR0015025 A BR 0015025A BR 0015025 A BR0015025 A BR 0015025A BR 0015025 A BR0015025 A BR 0015025A
- Authority
- BR
- Brazil
- Prior art keywords
- oral solution
- sweetening agent
- solution containing
- galantamine
- containing galantamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
"SOLUçãO ORAL CONTENDO GALANTAMINA E UM AGENTE ADOçANTE". A presente invenção refere-se a uma solução oral compreendendo galantamina ou um sal de adição farmaceuticamente aceitável da mesma e um agente adoçante; a invenção também se refere ao uso da dita solução oral e processo de preparação da mesma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99203512 | 1999-10-26 | ||
PCT/EP2000/010203 WO2001030318A1 (en) | 1999-10-26 | 2000-10-16 | Oral solution containing galanthamine and a sweetening agent |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015025A true BR0015025A (pt) | 2002-06-18 |
Family
ID=8240778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015025-8A BR0015025A (pt) | 1999-10-26 | 2000-10-16 | Solução oral contendo galantamina e um agente adoçante |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1237539B1 (pt) |
JP (1) | JP2003512415A (pt) |
KR (1) | KR100502391B1 (pt) |
CN (1) | CN1200691C (pt) |
AR (1) | AR026243A1 (pt) |
AT (1) | ATE306904T1 (pt) |
AU (1) | AU780826C (pt) |
BG (1) | BG65792B1 (pt) |
BR (1) | BR0015025A (pt) |
CA (1) | CA2388830C (pt) |
CZ (1) | CZ301996B6 (pt) |
DE (1) | DE60023341T2 (pt) |
DK (1) | DK1237539T3 (pt) |
EA (1) | EA005683B1 (pt) |
EE (1) | EE05230B1 (pt) |
ES (1) | ES2250211T3 (pt) |
HK (1) | HK1049619A1 (pt) |
HR (1) | HRP20020332B1 (pt) |
HU (1) | HUP0203484A3 (pt) |
IL (2) | IL149310A0 (pt) |
IS (1) | IS2628B (pt) |
MX (1) | MXPA02004149A (pt) |
NO (1) | NO332096B1 (pt) |
PL (1) | PL201694B1 (pt) |
SI (1) | SI1237539T1 (pt) |
SK (1) | SK285643B6 (pt) |
TW (1) | TW592725B (pt) |
UA (1) | UA76095C2 (pt) |
WO (1) | WO2001030318A1 (pt) |
ZA (1) | ZA200203313B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
CA2535613A1 (en) * | 2003-08-13 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Treatment of sleep disorders with cholinesterase inhibitors |
CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
US8709521B2 (en) * | 2007-05-22 | 2014-04-29 | The Coca-Cola Company | Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles |
DK2667715T3 (en) * | 2011-01-27 | 2017-10-23 | Neuren Pharmaceuticals Ltd | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID |
US20140107130A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals, LLC | Oral Solution Formulations of Aripiprazole |
JP6457582B2 (ja) * | 2017-04-14 | 2019-01-23 | エルメッド エーザイ株式会社 | ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
JPH10273435A (ja) * | 1997-01-29 | 1998-10-13 | Fujisawa Pharmaceut Co Ltd | 内服用液剤 |
-
2000
- 2000-10-16 SI SI200030782T patent/SI1237539T1/sl unknown
- 2000-10-16 UA UA2002054064A patent/UA76095C2/uk unknown
- 2000-10-16 TW TW089121526A patent/TW592725B/zh not_active IP Right Cessation
- 2000-10-16 AT AT00975872T patent/ATE306904T1/de active
- 2000-10-16 DK DK00975872T patent/DK1237539T3/da active
- 2000-10-16 WO PCT/EP2000/010203 patent/WO2001030318A1/en active IP Right Grant
- 2000-10-16 KR KR10-2002-7003258A patent/KR100502391B1/ko active IP Right Grant
- 2000-10-16 BR BR0015025-8A patent/BR0015025A/pt not_active Application Discontinuation
- 2000-10-16 IL IL14931000A patent/IL149310A0/xx active IP Right Grant
- 2000-10-16 AU AU13849/01A patent/AU780826C/en not_active Expired
- 2000-10-16 SK SK530-2002A patent/SK285643B6/sk not_active IP Right Cessation
- 2000-10-16 EE EEP200200213A patent/EE05230B1/xx unknown
- 2000-10-16 CA CA002388830A patent/CA2388830C/en not_active Expired - Lifetime
- 2000-10-16 ES ES00975872T patent/ES2250211T3/es not_active Expired - Lifetime
- 2000-10-16 CZ CZ20021329A patent/CZ301996B6/cs not_active IP Right Cessation
- 2000-10-16 DE DE60023341T patent/DE60023341T2/de not_active Expired - Lifetime
- 2000-10-16 EA EA200200486A patent/EA005683B1/ru not_active IP Right Cessation
- 2000-10-16 HU HU0203484A patent/HUP0203484A3/hu unknown
- 2000-10-16 MX MXPA02004149A patent/MXPA02004149A/es active IP Right Grant
- 2000-10-16 EP EP00975872A patent/EP1237539B1/en not_active Expired - Lifetime
- 2000-10-16 JP JP2001532738A patent/JP2003512415A/ja active Pending
- 2000-10-16 PL PL362849A patent/PL201694B1/pl unknown
- 2000-10-16 CN CNB008147388A patent/CN1200691C/zh not_active Expired - Lifetime
- 2000-10-25 AR ARP000105621A patent/AR026243A1/es not_active Application Discontinuation
-
2002
- 2002-02-28 IS IS6291A patent/IS2628B/is unknown
- 2002-03-20 BG BG106534A patent/BG65792B1/bg unknown
- 2002-04-15 HR HR20020332A patent/HRP20020332B1/xx not_active IP Right Cessation
- 2002-04-24 IL IL149310A patent/IL149310A/en unknown
- 2002-04-25 ZA ZA200203313A patent/ZA200203313B/xx unknown
- 2002-04-26 NO NO20022003A patent/NO332096B1/no not_active IP Right Cessation
-
2003
- 2003-03-10 HK HK03101718A patent/HK1049619A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200100495A (et) | Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim | |
CA2304704A1 (en) | Formulations and methods for reducing toxicity of antineoplastic agents | |
TNSN97015A1 (fr) | Nouveaux derives de 19-nor-pregnene. | |
DK275488D0 (da) | Indolonderivater | |
BR9809468A (pt) | Formulações farmacêuticas contendo voriconazol | |
BR0014939A (pt) | Oligossacarìdeos, processo de preparação de oligossacarìdeos, composições farmacêuticas, e, utilização de oligossacarìdeos | |
NO20002686L (no) | Forbedring av Peyronies sykdom | |
PT992509E (pt) | Novos derivados macrolidos | |
EA199801028A1 (ru) | Применение производных п-аминофенола для проготовления фармацевтических композиций, используемых при лечении нейродегенеративных заболеваний | |
BR0015025A (pt) | Solução oral contendo galantamina e um agente adoçante | |
HK1029937A1 (en) | Use of phanquinone for the treatment of alzheimer s disease. | |
BR0011845A (pt) | Complexo farmacêutico | |
BR0112338A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
AP9801235A0 (en) | Erythromycin derivatives. | |
AU6519596A (en) | Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases | |
HUP0103149A3 (en) | Pharmaceutical composition for treatment of alzheimer's disease | |
MXPA99003849A (es) | Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina. | |
ES2179115T3 (es) | Formulaciones de estramustina con propiedades farmaceuticas mejoradas. | |
AU2001246518A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
UA3247S (uk) | Упаковка медичного препарату "клофелін" | |
IT1309447B1 (it) | Strumento chirurgico per l'estrazione dei denti. | |
MY134931A (en) | Oral galantamine solution | |
TH15815A (th) | การใช้อนุพันธ์เพรคเนม | |
UA1954S (uk) | Упаковка медичного препарату "димексид" | |
UA1958S (uk) | Упаковка медичного препарату "аспаркам" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |